Tofersen · Qalsody
RNA / oligonucleotide
Evidence outlook
Approved: Amyotrophic Lateral Sclerosis
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also approved (2)
- Slowing the progression of functional impairment in patients with amyotrophic lateral sclerosis with SOD1 mutation
- Qalsody is indicated for the treatment of adults with amyotrophic lateral sclerosis (ALS), associated with a mutation in the superoxide dismutase 1 (SOD1) gene.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
VALOR (Part C) NCT02623699 · Amyotrophic Lateral Sclerosis The trial was randomized, quadruple-blind, and placebo-controlled, with 176 participants overall and 108 in the pivotal part. The hard clinical primary endpoint, change in ALSFRS-R score at Week 28, was not statistically significant: the least-squares mean change was -7.0 with tofersen versus -8.1 with placebo, with a treatment difference of 1.2 (95% CI -3.19 to 5.53; p=0.9689), so the result supports moderate rather than strong evidence. Registry: NCT02623699 | 3 | Parts A and B: Number of Participants Experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs) (Part A: First dose up to Day 63; Part B: First dose up to Day 289); Parts A and B: Number of Participants With Clinically Significant Laboratory Abnormalities (Part A: Up to Day 57; Part B: Up to Day 169); Parts A and B: Number of Participants With Clinically Significant Vital Sign Abnormalities (Part A: Up to Day 57; Part B: Up to Day 169); Parts A and B: Number of Participants With Clinically Significant Physical Examination Abnormalities (Part A: Up to Day 57; Part B: Up to Day 169); Parts A and B: Number of Participants With Clinically Significant Neurological Examination Abnormalities (Part A: Up to Day 57; Part B: Up to Day 169); Parts A and B: Number of Participants With Clinically Significant 12-lead Electrocardiograms (ECGs) Abnormalities (Part A: Up to Day 57; Part B: Up to Day 169); Parts A and B: PK Parameter of BIIB067 in Plasma: Maximum Observed Concentration (Cmax) (Part A: Pre-dose, 1, 2, 4, 6 hrs post-dose on Day 1; Part B: Pre-dose, 1, 2, 4, 6 hrs post-dose on Day 1 and 1, 2, 4, 6 hrs post-dose on Day 85); Parts A and B: PK Parameter of BIIB067 in Plasma: Time to Reach Maximum Observed Concentration (Tmax) (Part A: Pre-dose, 1, 2, 4, 6 hrs post-dose on Day 1; Part B: Pre-dose, 1, 2, 4, 6 hrs post-dose on Day 1 and 1, 2, 4, 6 hrs post-dose on Day 85); Parts A and B: PK Parameter of BIIB067 in Plasma: Area Under the Concentration-Time Curve From Time Zero to 24 Hours (AUC0-24h) (Parts A and B: Pre-dose, 1, 2, 4, 6 hrs post-dose on Day 1); Parts A and B: PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf) (Part A: Pre-dose Day 1, Days 29 and 57; Part B: Pre-dose Days 1, 15, 29, 57 and 85; Day 106 and 169); Parts A and B: PK Parameter of BIIB067 in Plasma: Area Under the Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUClast) (Part A: Pre-dose Day 1, Days 29 and 57; Part B: Pre-dose Days 1, 15, 29, 57 and 85; Day 106 and 169); Parts A and B: PK Parameter of BIIB067 in Plasma: Apparent Terminal Elimination Half-life (t1/2) (Part A: Pre-dose Day 1, Days 29 and 57; Part B: Pre-dose Days 1, 15, 29, 57 and 85; Day 106 and 169); Parts A and B: PK Parameters of BIIB067 in CSF Levels: Terminal Elimination Half-life (t1/2) (Part A: Pre-dose Day 1, Days 29 and 57; Part B: Pre-dose Days 1, 15, 29, 57 and 85; Day 106 and 169); Part C: Change From Baseline in Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Total Score at Week 28 (Baseline, Week 28 (Day 197)) 2021-07-16 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (3)
What this study did
What this study did
What this study did
Phase 2 (1)
What this study did
Phase 1 (1)
What this study did
Phase 4 (1)
What this study did
Competitive landscape
Other SOD1 drugs
1 other tracked programme targets this mechanism, none of them ahead of this one.
This drug's own stage for Amyotrophic Lateral Sclerosis: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Tofersen (Qalsody): this drug | Approved | RNA / oligonucleotide | SOD1 | Partial signal | No reviewed efficacy summary in this indication | |
| Edaravone (Radicava ORS) | Approved | Small molecule | Reactive oxygen species (ROS) | Weak signal | Featured results are safety only in this race | |
| Masitinib | Phase 3 | Small molecule | KIT (c-Kit), also PDGFR and Lyn/Fyn kinases | not yet graded | No reviewed efficacy summary in this indication | |
| Ulefnersen | Phase 3 | RNA / oligonucleotide | FUS | Reliable signal | NCT04768972: FUSION (NCT04768972): ulefnersen met its primary endpoint, a joint rank (win-ratio style) analysis of time to death/permanent ventilation, time to rescue, and change in ALSFRS-R score to Day 505 vs placebo; p=0.0005. | |
| CB03-154 | Phase 2/3 | Small molecule | KCNQ2/3 (Kv7.2/7.3) potassium channel (opener) | not yet graded | No reviewed efficacy summary in this indication | |
| CNM-Au8 | Phase 2/3 | Nanoparticle | mitochondrial energy metabolism | not yet graded | No reviewed efficacy summary in this indication | |
| Ibudilast | Phase 2/3 | Small molecule | PDE4 and PDE10; macrophage migration inhibitory factor (MIF) | not yet graded | No reviewed efficacy summary in this indication | |
| Tazbentetol (SPG302) | Phase 2/3 | Small molecule | Dendritic spine density | Weak signal | Featured results are safety only in this race | |
| Dazucorilant | Phase 2 | Small molecule | Glucocorticoid receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Foralumab | Phase 2 | Monoclonal antibody | CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| ALN-SOD | Phase 1/2 | RNA / oligonucleotide | SOD1 | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Qalsody (Tofersen) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (3)
January 2027 (1)
What to watch
May 2027 (1)
What to watch
August 2027 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent